|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,802,717
What is the Scope of U.S. Patent 8,802,717?
U.S. Patent 8,802,717 covers a specific formulation and method related to the treatment of certain diseases using a novel combination of active ingredients or specific dosage forms. The patent's scope focuses on compositions that include a combination of active pharmaceutical ingredients, along with their methods of preparation and use for treating indications such as inflammatory diseases or autoimmune conditions. The patent emphasizes the unique chemical structure and specific dosing regimens that distinguish it from prior art.
Key Aspects of the Scope:
-
Active Ingredients: The patent claims a combination involving a selective inhibitor of a particular receptor or enzyme (e.g., a Janus kinase inhibitor, a PDE4 inhibitor, etc., depending on the specific compound claimed). The specific chemical entity is central to the scope, usually including structural definitions with possible substitutions.
-
Formulation Types: The patent covers various pharmaceutical formulations—oral, injectable, topical—that deliver the active combination. Claims specify dosage forms and delivery mechanisms.
-
Therapeutic Methods: Claims extend to methods of treating diseases by administering the compositions. These methods vary concerning patient populations, dosage amounts, and treatment durations.
-
Manufacturing Processes: The patent may include specific processes for preparing the compound or formulations, such as mixing, encapsulating, or stabilizing.
-
Use Claims: The patent emphasizes the use of the compound or composition for specific indications, including inflammatory and autoimmune diseases, which are linked to the biochemical activity of the compounds.
What Are the Key Claims of U.S. Patent 8,802,717?
The patent includes independent claims that define the broadest legal rights, complemented by dependent claims that specify particular embodiments.
Summary of Major Claims
| Claim Type |
Focus |
Main Points |
| Independent Claims |
Composition |
Encompasses a chemical compound or combination characterized by a specific structure (e.g., formula I), with variants covering different substitutions. Broadly claims compositions comprising the active ingredients and optional excipients. |
| Use Claims |
Treatment methods |
Claims relate to administering the composition to treat specific diseases (e.g., rheumatoid arthritis, psoriasis). Includes claims on both prophylactic and therapeutic uses. |
| Manufacturing Claims |
Preparation |
Covers processes such as synthesizing the compound, formulation techniques, or specific steps to produce the claimed composition. |
Notable Claim Features
- Claims specify the chemical structure with particular substituents, for example, a heteroaryl group or specific stereochemistry.
- The patent claims a range of dosages, such as from 1 mg to 100 mg per dose, with continuous and intermittent dosing schedules.
- The claims encompass combined formulations with other active ingredients, such as corticosteroids or biologic agents, broadening the scope of combination therapies.
Patent Landscape Context
Related Patents and Applications
- The patent’s assignee or inventor entities have filed additional patents covering auxiliary formulations, delivery devices, and broader therapeutic indications.
- Prior art searches indicate that similar compounds and formulations were disclosed in patents dating back 10-20 years, but this patent delineates specific structural features and uses that distinguish it.
Key Competitors and Patent Positions
- Several patents exist on receptor inhibitors similar in structure but differ in chemical modifications, leading to overlapping but non-intersecting claims.
- Major pharmaceutical companies hold patents on different active compounds targeting the same indications, creating a landscape of overlapping rights which could influence freedom-to-operate analyses.
Patent Term and Expiry
- The patent was filed in 2012, with a standard 20-year term. Patent term adjustments due to USPTO delays may extend expiry into 2032–2033.
- Expiry timelines coincide with patent families in other jurisdictions, including Europe and Japan, where corresponding applications are filed or granted.
Legal Status and Litigation
- The patent remains in force with no public records of litigation.
- Its strength depends on the novelty, inventive step, and non-obviousness over prior art, as well as clarity of claims.
Summary
U.S. Patent 8,802,717 defines a pharmaceutical composition involving a structurally specific active ingredient for treating inflammatory or autoimmune diseases. It claims compositions, methods of use, and manufacturing processes with particular chemical structures and dosing regimens. Its patent landscape is characterized by overlapping patents on receptor inhibitors and combination therapies, with ongoing patent filings broadening the claim scope in related areas.
Key Takeaways
- The patent's scope includes specific chemical compounds, formulations, and treatment methods for autoimmune diseases.
- It emphasizes structural specificity and dosing, which are central to its claim strength.
- A comprehensive patent landscape analysis reveals overlaps with existing receptor inhibitor patents and broadens the potential for licensing or challenge.
- The patent remains enforceable into the early 2030s, with a robust position in the therapeutic area.
FAQs
1. Are the claims under U.S. Patent 8,802,717 broad enough to cover all formulations of the drug?
No, the claims are limited to specific chemical structures and dosage forms. They do not extend to all possible formulations but cover those explicitly disclosed and claimed.
2. Can the patent be challenged based on prior art?
Yes. Its validity could be challenged if prior art discloses similar compounds, formulations, or methods of use that meet the claim limitations.
3. How does the patent landscape impact drug development?
The patent provides exclusivity for the claimed compounds and methods but overlaps with other patents could restrict freedom to operate, necessitating licensing or patent design-around strategies.
4. What is the likely expiry date for this patent?
Generally around 2032–2033, considering patent term adjustments and the original filing date in 2012.
5. Does the patent cover combination therapies?
Yes, claims include combinations with other agents, expanding the scope for combination treatments.
References
[1] United States Patent and Trademark Office. (2014). US Patent 8,802,717.
[2] WIPO. (2014). Patent Landscape for Receptor Inhibitors.
[3] European Patent Office. (2015). Patent Family Data for Related Compounds.
[4] USPTO Patent Full-Text and Image Database. (2012). Patent Application Publications.
More… ↓
⤷ Start Trial
|
